FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington,	D.C.	20549	

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Sliman Joseph A.					2. Issuer Name and Ticker or Trading Symbol Synthetic Biologics, Inc. [SYN]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last)	((First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/17/2017							X	Officer (gives)			Other (s below)			
C/O SYNTHETIC BIOLOGICS, INC.,														Chief Medical Officer					
9605 MEDICAL CENTER DRIVE, SUITE 270				[4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv Line)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)												X							
ROCKVI	LLE	MD	20850									Form filed by More than One Reporting Person							
(City)	((State)	(Zip)																
			Table I - No	n-Deri	vati	/e Securit	ies A	٩cqu	iired, D	ispo	osed of, o	r Benefici	ally Own	ed					
Date				2. Transac Date Month/Da		Execution any	2A. Deemed Execution Date any (Month/Day/Ye				Acquired (A f (D) (Instr. 3,		5. Amount of Securities Beneficially (Following Re	Dwned Form: or Ind ported (Instr.		Direct (D) I rect (I) E	7. Nature of ndirect Beneficial Ownership		
						Code			٧	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1		nstr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)	tion Derivative Exp		Expir	expiration Date Securities Month/Day/Year) Derivativ			7. Title and Securities U Derivative S (Instr. 3 and	nderlying Security		9. Numb derivati Securiti Benefici Owned Followin	ve es ially	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exerc	: cisable	- 1	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)				
Stock Options	\$0.83	01/17/2017		А		188,927 ⁽¹⁾		01/1	17/2017 ⁽	1) (01/16/2024	Common Stock	188,927	\$0	188,927		D		

Explanation of Responses:

1. These options will vest monthly on a pro rata basis over 36 consecutive months.

/s/ Joseph Sliman

01/18/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.